Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

Studied

Phase 2 randomized trial comparing three tirzepatide doses with placebo for metabolic fatty liver inflammation and scarring.

Who / model

190 participants with biopsy-confirmed liver inflammation and moderate or severe fibrosis, studied for 52 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary outcome, inflammation resolution without worse scarring, occurred in 44%, 56% and 62% across increasing tirzepatide doses, versus 10%. The key secondary outcome, improved scarring without worse inflammation, occurred in 55%, 51% and 51%, versus 30%. Digestive adverse events were most common and usually mild or moderate.

Limits

Only 157 participants had evaluable follow-up biopsies. Missing results were estimated assuming the pattern seen with placebo.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary